Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Jorgensen

Showing results (531-540 of 567) with videos related to

Pageof 57
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
British Journal of Haematology|May 23, 2019
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapyHaitham Khogeer, Haitham Rahman, Nitin Jain, et al.
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|May 15, 2016
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenMichael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, et al.
Cancer|July 22, 2014
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)Michael E Rytting, Deborah A Thomas, Susan M O'Brien, et al.
Science (New York, N.Y.)|May 27, 2017
Jupiter's magnetosphere and aurorae observed by the Juno spacecraft during its first polar orbitsJ E P Connerney, A Adriani, F Allegrini, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Pageof 57

Showing results (531-540 of 567) with videos related to

Sort By:
Pageof 57
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid LeukemiaLina Han, Jeffrey L Jorgensen, Chris Brooks, et al.
Cancer|June 17, 2021
Hyper-CVAD plus ofatumumab versus hyper-CVAD plus rituximab as frontline therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: A propensity score analysisKoji Sasaki, Hagop M Kantarjian, Kiyomi Morita, et al.
British Journal of Haematology|May 23, 2019
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapyHaitham Khogeer, Haitham Rahman, Nitin Jain, et al.
British Journal of Haematology|October 23, 2015
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemiaFarhad Ravandi, Jeffrey L Jorgensen, Susan M O'Brien, et al.
The Lancet. Haematology|August 18, 2018
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trialTapan M Kadia, Jorge Cortes, Farhad Ravandi, et al.
Cancer|September 8, 2016
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemiaElias Jabbour, Nicholas J Short, Jeffrey L Jorgensen, et al.
American Journal of Hematology|May 15, 2016
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimenMichael E Rytting, Elias J Jabbour, Jeffrey L Jorgensen, et al.
Cancer|July 22, 2014
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL)Michael E Rytting, Deborah A Thomas, Susan M O'Brien, et al.
Science (New York, N.Y.)|May 27, 2017
Jupiter's magnetosphere and aurorae observed by the Juno spacecraft during its first polar orbitsJ E P Connerney, A Adriani, F Allegrini, et al.
Hemasphere|December 29, 2021
Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working PartyJesse M Tettero, Sylvie Freeman, Veit Buecklein, et al.
Pageof 57